Drug Profile

Verekitug - Upstream Biosciences

Alternative Names: ASP-7266; UPB-101

Latest Information Update: 10 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma
Developer Upstream Biosciences
Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
Mechanism of Action CRLF2 protein antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Asthma; Chronic obstructive pulmonary disease; Nasal polyps

Most Recent Events

03 Mar 2026 Upstream Bio plans regulatory interactions to initiate registrational trials in Asthma and Nasal polyps
03 Mar 2026 Updated efficacy data from a phase II VIBRANT trial in Nasal polyps released by Upstream Biosciences
11 Feb 2026 Adverse events and efficacy data from a phase II VALIANT trial in Asthma released by Upstream Bio

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com